Clinical trials: Diarrhea
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553747
- Testing
- Eluxadoline
- Where
- 253 sites in United States, Canada and 2 more
- Volunteers
- 1,146 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Campylobacter Infection
Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea
The purpose of this study is to assess the safety of increasing doses of a potential vaccine against Campylobacter with and without Alhydrogel®, an aluminum hydroxide adjuvant.
- Trial name
- CJCV1-01 (NCT02067676)
- Testing
- Capsule-Conjugate Campylobacter Vaccine (CJCV1), Alhydrogel®, aluminum hydroxide adjuvant (alum)
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Human Gut Microbiota
Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota
The purpose of this study is to compare and contrast the effects of a prebiotic (Trametes Versicolor), a probiotic (Saccharomyces boulardii) and an antibiotic (amoxicillin) on the gut microbiota of healthy volunteers.
- Trial name
- NCT01414010
- Testing
- Trametes versicolor extract, Saccharomyces boulardii, Amoxicillin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Irritable Bowel Syndrome
Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome
This research is studying whether changing an individual's diet may have an impact as a treatment or outcome for Irritable Bowel Syndrome (IBS).
- Trial name
- NCT04542018
- Testing
- a low FODMAP diet for 4 weeks
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- University of Michigan
Diarrhea, Metastatic Renal Cell Carcinoma
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
This randomized clinical trial studies how well probiotic yogurt supplement works in reducing diarrhea in patients with kidney cancer that has spread from the primary site to other places in the body (metastatic) and that are…
- Conditions
- Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Trial name
- NCT02944617
- Testing
- Laboratory Biomarker Analysis, Micronutrient-Fortified Probiotic Yogurt, VEGF-TKI
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Clostridium Difficile Infection
Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)
The purpose of this study is to determine whether Fecal Microbiota Therapy (FMT) is effective vs. placebo in the prevention of C. difficile infection recurrence.
- Trial name
- MATCH (NCT03005379)
- Testing
- Fecal Microbiota Therapy (FMT)
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- VA Office of Research and Development
Drug and/or Toxin-induced Diarrhea
Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
This is a randomized, stratified, double-blind, double-dummy, parallel group, placebo-controlled, dose finding, multicentre, multinational, phase II study in patient with colorectal cancer receiving 5- Fluorouracil (5-FU)-based…
- Trial name
- NCT02383810
- Testing
- Elsiglutide
- Where
- 54 sites in Belarus, Bulgaria and 6 more
- Volunteers
- 498 people
- Sponsor
- Helsinn Healthcare SA
Clostridioides Difficile Infection
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.
- Trial name
- Ri-CoDIFy 3 (NCT04802837)
- Testing
- Ridinilazole, Vancomycin
- Where
- 18 sites in United States
- Volunteers
- 2 people
- Sponsor
- Summit Therapeutics
Irritable Bowel Syndrome
Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome
In patients with IBS, will supplementation with a probiotic demonstrate symptomatic efficacy and will the probiotic influence gut microflora and thus improve clinical outcomes, as compared to no intervention.
- Trial name
- NCT01886781
- Testing
- Lactobacillus plantarum 299v, Run in period, Wash - out period
- Where
- South Africa
- Volunteers
- 81 people
- Sponsor
- University of Stellenbosch
Prevention of Travelers' Diarrhea
LT Vaccine Patch Self-Administration Study
To evaluate the immune responses achieved following self-administered heat-labile enterotoxin of E. coli (LT) vaccination by transcutaneous immunization compared to the immune responses achieved by clinician-administered…
- Trial name
- NCT00565461
- Testing
- heat-labile enterotoxin of E. coli (LT)
- Where
- 3 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
C. Difficile
Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route
The objective of the study is to investigate the safety of a frozen or lyophilized inoculum administered, respectively, by retention enema or capsules in patients with recurrent C. difficile associated diarrhea (RCDAD).
- Trial name
- NCT02449174
- Testing
- Frozen Microbiota, Lyophilized Microbiota
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- The University of Texas Health Science Center, Houston
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel…
- Trial name
- NCT01553591
- Testing
- Eluxadoline
- Where
- 283 sites in United States, Canada and 1 more
- Volunteers
- 1,282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Lymphocytic Colitis, Diarrhea
Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
Patients will receive budesonide or placebo for the treatment of active lymphocytic colitis. This study includes stool collections, blood draws, weekly questionnaires and a sigmoidoscopy.
- Trial name
- NCT00217022
- Testing
- Budesonide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Cancer
Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
Diarrhoea is the most commonly reported adverse event (AE) associated with Lapatinib treatment, and is also commonly associated with Capecitabine treatment.
- Trial name
- NCT02294786
- Testing
- Lapatinib, Capecitabine, Octreotide
- Where
- 17 sites in Czechia, Israel and 3 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Clostridium Difficile-associated Diarrhea (CDAD)
IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff
In this trial, eligible patients will be randomly assigned to receive a single dose of 400 mg/kg of IVIG or a normal saline infusion as placebo over 4-6 hours, in addition to their usual medications for CDAD.
- Trial name
- NCT00177970
- Testing
- intravenous immunoglobulin G (IVIG)
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Pittsburgh
Antibiotics Associated Colitis, Pulmonary Infection
Effect of Probiotic Lactobacilli (Lacidofil Cap®) for the Prevention of Antibiotic-Associated Diarrhea
Antibiotic-Associated Diarrhea (AAD) is a common complication of antibiotic use. The frequency of AAD can be high (26 - 60%) or moderate (13-29%) during hospital outbreaks and is relatively infrequent in outpatients.
- Trial name
- NCT01058356
- Where
- South Korea
- Volunteers
- 214 people
- Sponsor
- Pharmbio Korea Co., Ltd.
Diarrhea, Gastrointestinal Complications
Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy
RATIONALE: Cyclophosphamide may help control the symptoms of autoimmune enteropathy . PURPOSE: This phase II trial is studying how well cyclophosphamide works in treating young patients with severe autoimmune enteropathy.
- Conditions
- Diarrhea, Gastrointestinal Complications, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00258180
- Testing
- filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Diarrhea
Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
This is a research study about an experimental (investigational) oral ETEC vaccine (ACE527). ACE527 is a live attenuated vaccine that is being made to prevent disease from enterotoxigenic Escherichia coli (ETEC), which causes…
- Trial name
- NCT01739231
- Testing
- ACE527, dmLT, H10407 challenge strain
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- PATH
Diarrhea
Rifaximin for Prevention of Travellers' Diarrhea
The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.
- Trial name
- NCT00742469
- Testing
- Rifaximin
- Where
- Mexico
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Fecal Incontinence
Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence
The purpose of this study is to evaluate and compare treatment with fiber and loperamide for fecal incontinence.
- Trial name
- FIRM (NCT00727649)
- Testing
- Psyllium powder, Loperamide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- US Department of Veterans Affairs